Search results for "MEDLINE"

showing 10 items of 2097 documents

Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients

2011

Endoscopic local procedures are increasingly applied in patients with superficial esophageal cancer as an alternative to radical oncologic resection. The objective of this article is to determine the risk of nodal metastases in submucosal (sm) esophageal cancer, comparing the two predominating histologic tumor types, squamous cell cancer (SCC) and adenocarcinoma (ADC).A query of PubMed, MEDLINE, Embase and Cochrane Library (1980-2009) using predetermined search terms revealed 675 abstracts, of which 485 full-text articles were reviewed. A total of 105 articles met the selection criteria. A review of article references and consultation with experts revealed additional articles for inclusion.…

Oncologymedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentMEDLINEAdenocarcinomaCochrane LibraryRisk AssessmentEsophagusRisk FactorsInternal medicineCarcinomaHumansMedicineNeoplasm InvasivenessLymph nodeNeoplasm StagingMucous MembraneHepatologybusiness.industryPatient SelectionGastroenterologyEsophageal cancermedicine.diseaseEsophagectomymedicine.anatomical_structureEsophagectomyLymphatic MetastasisCarcinoma Squamous CellLymph Node ExcisionAdenocarcinomaEsophagoscopyRadiologybusinessRisk assessmentExpert Review of Gastroenterology & Hepatology
researchProduct

Integration of oncology and palliative care: a Lancet Oncology Commission.

2018

© 2018 Elsevier Ltd Full integration of oncology and palliative care relies on the specific knowledge and skills of two modes of care: the tumour-directed approach, the main focus of which is on treating the disease; and the host-directed approach, which focuses on the patient with the disease. This Commission addresses how to combine these two paradigms to achieve the best outcome of patient care. Randomised clinical trials on integration of oncology and palliative care point to health gains: improved survival and symptom control, less anxiety and depression, reduced use of futile chemotherapy at the end of life, improved family satisfaction and quality of life, and improved use of health-…

Oncologymedicine.medical_specialtyHealth Knowledge Attitudes PracticePalliative careAttitude to DeathAttitude of Health PersonnelMEDLINEMedical Oncology03 medical and health sciences0302 clinical medicineQuality of life (healthcare)nursingMultidisciplinary approachInternal medicineNeoplasmsHealth caremedicinecancerHumans030212 general & internal medicineOncology & CarcinogenesisCooperative BehaviorPatient Care Teambusiness.industryDelivery of Health Care IntegratedPalliative CareMental health3. Good healthIntegrated careClinical trialTreatment OutcomeOncology030220 oncology & carcinogenesisCritical PathwaysQuality of LifeInterdisciplinary CommunicationbusinessThe Lancet. Oncology
researchProduct

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

2015

Abstract Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future…

Oncologymedicine.medical_specialtyInternational CooperationImmunologyMEDLINEMedical OncologyBiochemistryMyeloproliferative DisordersSurveys and QuestionnairesInternal medicinehemic and lymphatic diseasesmedicineHumansResponse criteriaCell ProliferationClinical Trials as TopicMyeloproliferative DisordersAdult patientsSurrogate endpointbusiness.industryStandard treatmentMyelodysplastic syndromesfood and beveragesCell BiologyHematologymedicine.diseaseClinical trialPhenotypeTreatment OutcomeHematologic NeoplasmsMyelodysplastic SyndromesMutationPractice Guidelines as TopicDisease ProgressionPhysical therapybusinessAlgorithmsPerspectives
researchProduct

Incomplete Surgery for Bronchial Cystic Adenoid Carcinoma: A Therapeutic Alternative

2013

Oncologymedicine.medical_specialtyLung Neoplasmsbusiness.industryGeneral EngineeringMEDLINEmedicine.diseaseAdenoidCarcinoma Adenoid CysticCarcinoma Bronchogenicmedicine.anatomical_structureInternal medicineAdenoidsmedicineCarcinomaHumansRadiologybusinessCirugía Española (English Edition)
researchProduct

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Int…

2011

The Gynecological Cancer Intergroup (GCIG) has previously reached consensus regarding the criteria that should be used in clinical trial protocols to define progression-free survival after first-line therapy as well as the criteria to define response to treatment in recurrent disease using the serum marker CA 125 and has specified the situations where these criteria should be used. However, the publications did not include detailed definitions, nor were they written to accommodate the new version of Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1) now available. Thus, we recommend that the definitions described later in detail are incorporated into clinical trial…

Oncologymedicine.medical_specialtyMEDLINEAntineoplastic AgentsDisease-Free SurvivalInternal medicinemedicineRecurrent diseaseHumansIn patientOvarian NeoplasmsClinical Trials as Topicbusiness.industryObstetrics and Gynecologymedicine.diseaseGynecological cancerResponse to treatmentSurgeryClinical trialOncologyResponse Evaluation Criteria in Solid TumorsCA-125 AntigenDisease ProgressionFemaleHuman medicineNeoplasm Recurrence LocalOvarian cancerbusiness
researchProduct

Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review

2019

Background: The goal of this paper was to identify available biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw (BRONJ). Material and Methods: Case-control studies comparing the different concentrations of a series of molecules detected in serum and urine as matrices of BRONJ affected patients vs. non-affected were included. PRISMA guidelines for systematic reviews were used for the present paper. Two reviewers independently screened electronic databases (Medline, Web of science, and The Cochrane Library) and performed hand searches. Risk of bias assessment of selected studies was performed by the Newcastle-Ottawa Scale. This study is registered as PROSPERO CR…

Oncologymedicine.medical_specialtyMEDLINEReviewCochrane LibraryRisk Assessment03 medical and health sciences0302 clinical medicineBiphosphonatePredictive Value of TestsInternal medicinemedicineHumansGeneral DentistryOral Medicine and PathologyBisphosphonate-associated osteonecrosis of the jawbusiness.industryCase-control study030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Systematic reviewOtorhinolaryngologyCase-Control Studies030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgerybusinessRisk assessmentOsteonecrosis of the jawBiomarkers
researchProduct

Periodontitis as a risk factor for head and neck cancer

2020

Background Periodontitis may be associated with the development of head and neck cancer (HNC). A literature review was conducted to understand the possible association between them. Material and Methods Articles published in the PubMed database from January 1999 and May 2020 were retrieved. Limitations of the studies and biological mechanisms were discussed. Results A total of 4,232 articles were found. Of these, 13 were analyzed according to inclusion criteria. Most papers found some association between periodontitis and HNC, although differences in periodontal evaluation, sample size, study design and tumor sites were observed. Porphyromonas gingivalis appears to increase the chance of bo…

Oncologymedicine.medical_specialtyMEDLINEReviewRisk FactorsInternal medicinemedicineGenetic predispositionHumansPeriodontologyRisk factorPeriodontitisGeneral DentistryPorphyromonas gingivalissolid organ transplantationUNESCO:CIENCIAS MÉDICASPeriodontitisbiologyPotential riskbusiness.industryHead and neck cancermedicine.diseaseOmicsbiology.organism_classificationOtorhinolaryngologyHead and Neck Neoplasmsoral healthoral health-related quality of lifeSurgerybusinessPorphyromonas gingivalis
researchProduct

Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan’s Efficacy:

2021

n/a.

Oncologymedicine.medical_specialtyMEDLINEeGFR declineType 2 diabetesEgfr declineendothelin receptor antagonistlaw.inventionRandomized controlled triallawInternal medicinePost-hoc analysismedicinebusiness.industryEndothelin receptor antagonistAtrasentan22/2 OA procedureGeneral Medicinemedicine.diseaseClinical trialNephrologyrandomized controlled trialtype 2 diabetesbusinesschronic kidney diseasemedicine.drugJournal of the American Society of Nephrology
researchProduct

Hematopoietic and lymphatic cancers in patients with periodontitis : a systematic review and meta-analysis

2019

Background Numerous studies have explored the correlation of periodontal disease (PD) with risk of hematopoietic and lymphatic cancers, but the findings were inconsistent. Therefore, we did a meta-analysis to ascertain the correlation of PD with risk of incident hematopoietic and lymphatic cancers. Material and Methods The authors searched relevant studies in databases (PubMed, Web of Science, and MEDLINE). The summary relative risk (RR) along with 95% confidence interval (CI) was calculated by use of random or fixed effects models. Results Six studies were included in qualitative synthesis. The pooled analysis revealed that PD was significantly associated with an increased risk of hematopo…

Oncologymedicine.medical_specialtyPopulationMEDLINEReview03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineNeoplasmsmedicineHumansPeriodontologyRisk factoreducationPeriodontitisGeneral DentistryPeriodontitiseducation.field_of_studybusiness.industryHematopoietic Stem Cell Transplantation030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Confidence intervalLymphatic systemOtorhinolaryngologyMeta-analysisRelative riskUNESCO::CIENCIAS MÉDICASSurgerybusiness
researchProduct

Osteonecrosis of the jaws produced by sunitinib : a systematic review

2019

Background Tyrosine kinase receptor family is involved in tumor growth, pathological angiogenesis and the progression (metastasis) of cancer. Sunitinib (Sutent®) inhibits members of the tyrosine kinase receptor family affecting the induction of angiogenesis and tumor progression. It is not clear if sunitinib increases the risk of osteonecrosis of the jaws (ONJ). The aim of this study was to carry out a systematic review about ONJ related to sunitinib, describing existing cases and possible associated risk factors. Material and Methods The PubMed/MEDLINE and Cochrane Library databases were searched without date restriction up to September 2018. We included prospective and retrospective obser…

Oncologymedicine.medical_specialtyPopulationMEDLINEReviewCochrane Library03 medical and health sciences0302 clinical medicineInternal medicineSunitinibmedicineHumansProspective StudieseducationProspective cohort studyGeneral DentistryRetrospective Studieseducation.field_of_studyOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesSunitinibbusiness.industryOsteonecrosisRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Cross-Sectional StudiesDenosumabOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryObservational studybusinessmedicine.drug
researchProduct